TOKYO, April 15, 2025--Elix, Inc. (CEO: Shinya Yuki / HQ: Tokyo, hereinafter "Elix"), an AI drug discovery company with the mission of "Rethinking Drug Discovery", today announced that it has ...

PRISM BioLab, Co. Ltd. ("PRISM BioLab"), a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, today announced ...

Elix and PRISM BioLab Join Forces to Accelerate AI-Driven Drug Discovery for Challenging Protein-Protein Interaction Targets Provided by Business Wire Apr 15, 2025, 2:00:00 PM ...

PRISM BioLab, Co. Ltd., a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, announced that it has entered into a ...